(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.85%) $83.14
(-1.16%) $1.619
(-0.32%) $2 339.80
(-0.04%) $27.53
(0.53%) $927.00
(-0.20%) $0.933
(-0.20%) $11.00
(-0.25%) $0.798
(0.00%) $92.17
7.29% $ 0.629
Live Chart Being Loaded With Signals
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 1.78M |
Średni wolumen | 1.24M |
Kapitalizacja rynkowa | 127.96M |
EPS | $-53.13 ( 2023-09-29 ) |
Last Dividend | $0.360 ( 2023-03-06 ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.29 |
ATR14 | $0.0360 (5.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-06 | Kelly Steven | Buy | 600 000 | Stock Option (Right to Buy) |
2023-06-06 | Zweifach Sanford S | Buy | 38 700 | Stock Option (Right to Buy) |
2023-06-06 | Morris Richard Steven | Buy | 238 000 | Stock Option (Right to Buy) |
2023-06-06 | Torok Michael | Buy | 38 700 | Stock Option (Right to Buy) |
2023-06-06 | Klichinsky Michael | Buy | 238 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
76.64 |
Last 87 transactions |
Buy: 18 644 112 | Sell: 1 508 721 |
Wolumen Korelacja
Sesen Bio Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
BOCH | 0.945 |
SHSP | 0.905 |
DYNT | 0.846 |
SGC | 0.836 |
MMAC | 0.83 |
WWD | 0.829 |
SYKE | 0.826 |
LIVE | 0.825 |
DGLY | 0.823 |
ECOR | 0.817 |
10 Najbardziej negatywne korelacje | |
---|---|
GAINL | -0.898 |
APOP | -0.887 |
TDAC | -0.884 |
RMRM | -0.88 |
ISNS | -0.872 |
SVOK | -0.829 |
VERA | -0.822 |
AHPI | -0.801 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sesen Bio Inc Korelacja - Waluta/Towar
Sesen Bio Inc Finanse
Annual | 2022 |
Przychody: | $40.00M |
Zysk brutto: | $40.00M (100.00 %) |
EPS: | $-1.990 |
FY | 2022 |
Przychody: | $40.00M |
Zysk brutto: | $40.00M (100.00 %) |
EPS: | $-1.990 |
FY | 2021 |
Przychody: | $26.54M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.00184 |
FY | 2020 |
Przychody: | $11.24M |
Zysk brutto: | $11.24 (0.00 %) |
EPS: | $-0.190 |
Financial Reports:
No articles found.
Sesen Bio Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.360 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.360 | 2023-03-06 |
Last Dividend | $0.360 | 2023-03-06 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.360 | -- |
Avg. Dividend % Per Year | 18.77% | -- |
Score | 4.82 | -- |
Div. Sustainability Score | 5.13 | |
Div.Growth Potential Score | 0.276 | |
Div. Directional Score | 2.70 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.360 | 56.30% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.605 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.761 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.910 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.53 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.27 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 6.42 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0257 | -1.500 | 9.57 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 11.34 | 1.000 | 6.91 | 6.91 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0199 | 2.00 | 9.99 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.0166 | 2.00 | 9.99 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0593 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 1.000 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.510 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.292 | 1.000 | 9.49 | 9.49 | [0.2 - 2] |
assetTurnoverTTM | 0.474 | 0.800 | -0.172 | -0.138 | [0.5 - 2] |
Total Score | 5.13 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.312 | 1.000 | -0.133 | 0 | [1 - 100] |
returnOnEquityTTM | -0.910 | 2.50 | -7.21 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.0166 | 2.00 | 9.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0199 | 2.00 | 9.99 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0158 | 1.000 | -2.10 | 0 | [0.1 - 0.5] |
Total Score | 0.276 |
Sesen Bio Inc
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej